晚期胆管癌中活性化疗方案的识别：过去二十年化疗试验综述
Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.
作者信息
Ulahannan Susanna V, Rahma Osama E, Duffy Austin G, Makarova-Rusher Oxana V, Kurtoglu Metin, Liewehr David J, Steinberg Seth M, Greten Tim F
机构信息
Gastrointestinal Malignanacies Section, Thoracic & GI-Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.
出版信息
Hepat Oncol. 2015 Jan 1;2(1):39-50. doi: 10.2217/hep.14.36.
Biliary tract carcinoma is a rare malignancy. We performed a comprehensive analysis of published prospective clinical trials in advanced biliary tract carcinoma in an attempt to identify active regimens in this setting. We searched PubMed and abstracts presented at the American Society of Clinical Oncology, Gastrointestinal Cancer Symposium, European Society of Medical Oncology and European Cancer Organization conferences for clinical trials in this disease. We found 83 trials. The effect of gemcitabine on overall survival benefit showed a strong trend (p = 0.014) and an improvement in progression-free survival (p = 0.003). Gemcitabine-based regimens containing 5-fluorouracil showed a trend toward an improved overall survival (p = 0.047) relative to platinum agents. Our findings support gemcitabine as the chemotherapy backbone for the treatment of patients with cholangiocarcinoma. Gemcitabine plus 5-fluorouracil combinations warrant further investigations.
胆管癌是一种罕见的恶性肿瘤。我们对已发表的晚期胆管癌前瞻性临床试验进行了全面分析，试图确定该情况下的有效治疗方案。我们检索了PubMed以及在美国临床肿瘤学会、胃肠道癌症研讨会、欧洲医学肿瘤学会和欧洲癌症组织会议上发表的摘要，以查找有关该疾病的临床试验。我们找到了83项试验。吉西他滨对总生存获益的影响呈现出强烈趋势（p = 0.014），无进展生存期有所改善（p = 0.003）。相对于铂类药物，含5-氟尿嘧啶的基于吉西他滨的治疗方案显示出总生存改善的趋势（p = 0.047）。我们的研究结果支持将吉西他滨作为胆管癌患者治疗的化疗基础药物。吉西他滨加5-氟尿嘧啶联合方案值得进一步研究。
Zotero 插件